Drug repurposing in the treatment of chronic inflammatory diseases

IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Shivmuni Sarup, Alexander G. Obukhov, Shubhi Raizada, Rajat Atre, Mirza S. Baig
{"title":"Drug repurposing in the treatment of chronic inflammatory diseases","authors":"Shivmuni Sarup,&nbsp;Alexander G. Obukhov,&nbsp;Shubhi Raizada,&nbsp;Rajat Atre,&nbsp;Mirza S. Baig","doi":"10.1186/s43094-024-00730-1","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Chronic inflammation is an increasing global healthcare challenge with limited effective treatment options. Developing medications for chronic diseases requires high financial investment and a long duration. Given these challenges, alternative strategies are needed. Here, we focus on one such strategy that holds great promise: drug repurposing, which involves identifying new therapeutic uses for existing drugs.</p><h3>Main body</h3><p>Here, we discuss the importance of two key transcription factors: nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1), in orchestrating complex pathophysiological signaling networks involved in chronic inflammatory diseases. Dysregulation of the NF-κB and AP1 signaling pathways have been associated with various diseases, such as cancer, inflammatory disease, and autoimmune disorders. This review emphasized that repurposed small-molecule inhibitors of these pathways have proven successful as therapeutic interventions. These compounds exhibit high degrees of specificity and efficacy in modulating NF-κB or AP-1 signaling, making them appealing candidates for treating chronic inflammatory conditions. This review discusses the therapeutic potential and action mechanisms of several repurposed small-molecule inhibitors for combating diseases caused by abnormal activation or inhibition of NF-κB and AP-1.</p><h3>Conclusion</h3><p>This concise review highlights the potential of repurposing small-molecule inhibitors targeting the NF-κB and AP-1 pathways as effective therapies for various chronic inflammatory diseases. While further experimental validation is needed, drug repurposing offers a promising strategy to bypass the existing lengthy and expensive new drug development processes, providing a faster and more economical route to novel treatments.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"10 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-024-00730-1","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-024-00730-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Chronic inflammation is an increasing global healthcare challenge with limited effective treatment options. Developing medications for chronic diseases requires high financial investment and a long duration. Given these challenges, alternative strategies are needed. Here, we focus on one such strategy that holds great promise: drug repurposing, which involves identifying new therapeutic uses for existing drugs.

Main body

Here, we discuss the importance of two key transcription factors: nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1), in orchestrating complex pathophysiological signaling networks involved in chronic inflammatory diseases. Dysregulation of the NF-κB and AP1 signaling pathways have been associated with various diseases, such as cancer, inflammatory disease, and autoimmune disorders. This review emphasized that repurposed small-molecule inhibitors of these pathways have proven successful as therapeutic interventions. These compounds exhibit high degrees of specificity and efficacy in modulating NF-κB or AP-1 signaling, making them appealing candidates for treating chronic inflammatory conditions. This review discusses the therapeutic potential and action mechanisms of several repurposed small-molecule inhibitors for combating diseases caused by abnormal activation or inhibition of NF-κB and AP-1.

Conclusion

This concise review highlights the potential of repurposing small-molecule inhibitors targeting the NF-κB and AP-1 pathways as effective therapies for various chronic inflammatory diseases. While further experimental validation is needed, drug repurposing offers a promising strategy to bypass the existing lengthy and expensive new drug development processes, providing a faster and more economical route to novel treatments.

治疗慢性炎症性疾病的药物再利用
背景慢性炎症是一个日益严重的全球性医疗挑战,但有效的治疗方案却很有限。开发治疗慢性疾病的药物需要高额的资金投入和较长的疗程。鉴于这些挑战,需要采取替代策略。正文在此,我们讨论了两个关键转录因子:核因子卡巴B(NF-κB)和激活蛋白1(AP-1)在协调慢性炎症性疾病所涉及的复杂病理生理信号网络中的重要性。NF-κB和AP1信号通路的失调与癌症、炎症性疾病和自身免疫性疾病等多种疾病有关。这篇综述强调,这些通路的再用途小分子抑制剂已被证明是成功的治疗干预措施。这些化合物在调节 NF-κB 或 AP-1 信号传导方面表现出高度的特异性和有效性,使它们成为治疗慢性炎症的理想候选药物。本综述讨论了几种再利用小分子抑制剂的治疗潜力和作用机制,这些抑制剂可用于治疗因 NF-κB 和 AP-1 异常激活或抑制而引起的疾病。虽然还需要进一步的实验验证,但药物再利用提供了一种很有前景的策略,可以绕过现有的漫长而昂贵的新药开发过程,为新型疗法提供更快、更经济的途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
44
审稿时长
23 weeks
期刊介绍: Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信